恶性胸膜间皮瘤
Malignant pleural mesothelioma.
作者信息
Tsao Anne S, Wistuba Ignacio, Roth Jack A, Kindler Hedy Lee
机构信息
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA.
出版信息
J Clin Oncol. 2009 Apr 20;27(12):2081-90. doi: 10.1200/JCO.2008.19.8523. Epub 2009 Mar 2.
Abstract
Malignant pleural mesothelioma (MPM) is a deadly disease that occurs in 2,000 to 3,000 people each year in the United States. Although MPM is an extremely difficult disease to treat, with the median overall survival ranging between 9 and 17 months regardless of stage, there has been significant progress over the last few years that has reshaped the clinical landscape. This article will provide a comprehensive discussion of the latest developments in the treatment of MPM. We will provide an update of the major clinical trials that impact mesothelioma treatment in the resectable and unresectable settings, discuss the impact of novel therapeutics, and provide perspective on where the clinical research in mesothelioma is moving. In addition, there are controversial issues, such as the role of extrapleural pneumonectomy, adjuvant radiotherapy, and use of intensity-modulated radiotherapy versus hemithoracic therapy that will also be addressed in this manuscript.
摘要
恶性胸膜间皮瘤（MPM）是一种致命疾病，在美国每年有2000至3000人发病。尽管MPM是一种极难治疗的疾病，无论处于何阶段，总体中位生存期在9至17个月之间，但在过去几年里取得了重大进展，重塑了临床格局。本文将全面讨论MPM治疗的最新进展。我们将介绍影响可切除和不可切除情况下间皮瘤治疗的主要临床试验的最新情况，讨论新型疗法的影响，并展望间皮瘤临床研究的发展方向。此外，本文还将探讨一些有争议的问题，如胸膜外全肺切除术的作用、辅助放疗以及调强放疗与半胸放疗的应用。
相似文献
1
Malignant pleural mesothelioma.恶性胸膜间皮瘤
J Clin Oncol. 2009 Apr 20;27(12):2081-90. doi: 10.1200/JCO.2008.19.8523. Epub 2009 Mar 2.
2
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.恶性胸膜间皮瘤的新辅助化疗和胸膜外全肺切除术联合或不联合半胸部放疗 (SAKK 17/04)：一项随机、国际、多中心 2 期试验。
Lancet Oncol. 2015 Dec;16(16):1651-8. doi: 10.1016/S1470-2045(15)00208-9. Epub 2015 Nov 2.
3
Combined modality treatment for malignant pleural mesothelioma: a single-centre long-term survival analysis using extrapleural pneumonectomy.恶性胸膜间皮瘤的联合治疗模式：采用胸膜外全肺切除术的单中心长期生存分析。
Eur J Cardiothorac Surg. 2019 May 1;55(5):934-941. doi: 10.1093/ejcts/ezy385.
4
Malignant pleural mesothelioma: a comprehensive review.恶性胸膜间皮瘤：全面综述
Cancer Control. 2006 Oct;13(4):255-63. doi: 10.1177/107327480601300402.
5
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma.加速半胸放疗后行胸膜外全肺切除术治疗恶性胸膜间皮瘤。
J Thorac Cardiovasc Surg. 2016 Feb;151(2):468-73. doi: 10.1016/j.jtcvs.2015.09.129. Epub 2015 Oct 19.
6
Hemithoracic intensity-modulated radiotherapy using helical tomotherapy for patients after extrapleural pneumonectomy for malignant pleural mesothelioma.胸腔半野调强放疗技术在恶性胸膜间皮瘤行胸膜外全肺切除术后的应用。
J Radiat Res. 2012;53(2):288-94. doi: 10.1269/jrr.11130. Epub 2012 Feb 25.
7
A Narrative Review-Management of Malignant Pleural Effusion Related to Malignant Pleural Mesothelioma.中文译文：恶性胸膜间皮瘤相关恶性胸腔积液的叙述性综述：管理策略
Heart Lung Circ. 2023 May;32(5):587-595. doi: 10.1016/j.hlc.2023.02.004. Epub 2023 Mar 14.
8
Clinical experience of volumetric modulated arc therapy for malignant pleural mesothelioma after extrapleural pneumonectomy.胸膜外全肺切除术后容积调强弧形放疗治疗恶性胸膜间皮瘤的临床经验
J Radiat Res. 2015 Mar;56(2):315-24. doi: 10.1093/jrr/rru102. Epub 2015 Jan 18.
9
Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia.西澳大利亚州接受三联疗法的恶性胸膜间皮瘤患者的治疗结果。
J Thorac Oncol. 2009 Aug;4(8):1010-6. doi: 10.1097/JTO.0b013e3181ae25bf.
10
Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy.新辅助化疗、胸膜外全肺切除术及调强放疗治疗恶性胸膜间皮瘤的长期疗效
Radiat Oncol. 2015 Dec 30;10:267. doi: 10.1186/s13014-015-0575-5.
引用本文的文献
1
Twice as Effective? Pressurized Intra-Thoracic Aerosol Chemotherapy: New Frontiers in Pleural Mesothelioma.效果加倍？胸腔内加压雾化化疗：胸膜间皮瘤的新前沿
Med Sci (Basel). 2025 Jun 2;13(2):72. doi: 10.3390/medsci13020072.
2
Immune-related gene risk model establishment and role of key gene FUCA1 in malignant pleural mesothelioma.免疫相关基因风险模型的建立及关键基因FUCA1在恶性胸膜间皮瘤中的作用
Front Pharmacol. 2025 May 23;16:1577232. doi: 10.3389/fphar.2025.1577232. eCollection 2025.
3
Pretreatment platelet level is associated with tumor proliferation and prognosis in malignant pleural mesothelioma.治疗前血小板水平与恶性胸膜间皮瘤的肿瘤增殖及预后相关。
Gen Thorac Cardiovasc Surg. 2025 Apr 15. doi: 10.1007/s11748-025-02148-9.
4
PD-L1 pfeRNAs as blood-based predictors of treatment response of unresectable malignant pleural mesothelioma patients administered Durvalumab with cisplatin and pemetrexed as first-line therapy.程序性死亡配体1（PD-L1）的pfeRNAs作为不可切除恶性胸膜间皮瘤患者一线接受度伐利尤单抗联合顺铂和培美曲塞治疗反应的血液预测指标。
Noncoding RNA Res. 2025 Feb 21;12:34-41. doi: 10.1016/j.ncrna.2025.02.003. eCollection 2025 Jun.
5
M2-like tumor-associated macrophages may promote tumor progression in malignant pleural mesothelioma.M2样肿瘤相关巨噬细胞可能促进恶性胸膜间皮瘤的肿瘤进展。
Transl Oncol. 2025 Apr;54:102324. doi: 10.1016/j.tranon.2025.102324. Epub 2025 Feb 20.
6
A comprehensive multidisciplinary approach for identifying asbestos exposure among underground workers.一种用于识别地下工作者石棉暴露情况的综合多学科方法。
Rev Bras Med Trab. 2025 Jan 31;22(4):e20241271. doi: 10.47626/1679-4435-2024-1271. eCollection 2024 Oct-Dec.
7
Antigen targeting and anti-tumor activity of a novel anti-CD146 Pb internalizing alpha-radioimmunoconjugate against malignant peritoneal mesothelioma.针对恶性腹膜间皮瘤的新型抗 CD146 Pb 内化α-放射性免疫偶联物的抗原靶向和抗肿瘤活性。
Sci Rep. 2024 Oct 29;14(1):25941. doi: 10.1038/s41598-024-76778-z.
8
Malignant Pleural Mesothelioma: A Comprehensive Review.恶性胸膜间皮瘤：综述
J Clin Med. 2024 Sep 30;13(19):5837. doi: 10.3390/jcm13195837.
9
Deciphering the role of claudins in lung cancer.解读紧密连接蛋白在肺癌中的作用。
Front Oncol. 2024 Sep 19;14:1435535. doi: 10.3389/fonc.2024.1435535. eCollection 2024.
10
Dose-escalation, tolerability, and efficacy of intratumoral and subcutaneous injection of hemagglutinating virus of Japan envelope (HVJ-E) against chemotherapy-resistant malignant pleural mesothelioma: a clinical trial.瘤内及皮下注射日本血凝病毒包膜（HVJ-E）治疗化疗耐药性恶性胸膜间皮瘤的剂量递增、耐受性及疗效：一项临床试验
Cancer Immunol Immunother. 2024 Oct 3;73(12):243. doi: 10.1007/s00262-024-03815-1.
本文引用的文献
1
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.多中心、双盲、安慰剂对照、随机二期临床试验：吉西他滨/顺铂联合贝伐珠单抗或安慰剂治疗恶性间皮瘤患者。
J Clin Oncol. 2012 Jul 10;30(20):2509-15. doi: 10.1200/JCO.2011.41.5869. Epub 2012 Jun 4.
2
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.培美曲塞联合顺铂新辅助治疗后行胸膜外全肺切除术及放疗用于恶性胸膜间皮瘤的多中心II期试验
J Clin Oncol. 2009 Jun 20;27(18):3007-13. doi: 10.1200/JCO.2008.20.3943. Epub 2009 Apr 13.
3
Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.单药培美曲塞用于初治及经治的恶性胸膜间皮瘤患者：一项国际扩大可及项目的结果
J Thorac Oncol. 2008 Jul;3(7):764-71. doi: 10.1097/JTO.0b013e31817c73ec.
4
Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.培美曲塞联合顺铂或培美曲塞联合卡铂用于初治恶性胸膜间皮瘤患者：国际扩大可及项目的结果
J Thorac Oncol. 2008 Jul;3(7):756-63. doi: 10.1097/JTO.0b013e31817c73d6.
5
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.厄洛替尼联合贝伐单抗用于既往接受过治疗的恶性胸膜间皮瘤患者。
Cancer. 2008 Aug 15;113(4):808-14. doi: 10.1002/cncr.23617.
6
Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma.顺铂和长春瑞滨用于不可切除恶性胸膜间皮瘤的一线化疗。
Br J Cancer. 2008 Jul 8;99(1):44-50. doi: 10.1038/sj.bjc.6604421. Epub 2008 Jun 10.
7
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial.在恶性胸膜间皮瘤患者治疗中采用或不采用化疗进行症状主动控制（MS01）：一项多中心随机试验
Lancet. 2008 May 17;371(9625):1685-94. doi: 10.1016/S0140-6736(08)60727-8.
8
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.每周一次长春瑞滨治疗复发性恶性胸膜间皮瘤的疗效与安全性。
Lung Cancer. 2009 Jan;63(1):94-7. doi: 10.1016/j.lungcan.2008.04.001. Epub 2008 May 16.
9
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.培美曲塞联合最佳支持治疗与最佳支持治疗用于既往接受过治疗的晚期恶性胸膜间皮瘤患者的III期试验。
J Clin Oncol. 2008 Apr 1;26(10):1698-704. doi: 10.1200/JCO.2006.09.9887.
10
Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.培美曲塞与吉西他滨用于初治恶性胸膜间皮瘤的II期试验
J Clin Oncol. 2008 Mar 20;26(9):1465-71. doi: 10.1200/JCO.2007.14.7611.
Zotero 插件